Tukysa® (tucatinib) in combination with antibody-drug conjugate ado-trastuzumab emtansine improves progression-free survival in patients with previously treated her2-positive metastatic breast cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced data from the phase 3 her2climb-02 clinical trial of tukysa® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (kadcyla®). the combination showed a statistically significant improvement in progression-free survival (pfs), the study's primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (her2-positive) breast c.
SGEN Ratings Summary
SGEN Quant Ranking